On the significance of the trigger reaction in the action of the calicheamicin γI1 anti-cancer drug

被引:29
|
作者
Lindh R. [1 ]
Ryde U. [1 ]
Schütz M. [1 ]
机构
[1] Theoretical Chemistry, Chemical Center, S-221 00 Lund
关键词
Bergman reaction; Calicheamicin; Integral-direct MP2; Parallel MP2; Trigger reaction;
D O I
10.1007/s002140050254
中图分类号
学科分类号
摘要
The significance of the so-called trigger reaction in the reaction mechanism of the calicheamicin γI1 anti-cancer drug has been studied with ab initio quantum chemical methods. The structures of four fragments of calicheamicin γI1, consisting of either 39 or 41 atoms, have been fully optimized using the Becke-Perdew86 density functional method and the 6-31G* basis sets. The four structures constitute members of an isodesmic reaction for which the reaction energy is a direct measure of the change in activation energy of the Bergman reaction, caused by the structural rearrangements of the preceding trigger reaction. This difference in activation energy has been calculated with density functional theory, using the exchange-correlation functional mentioned above, and with second-order Møller-Plesset perturbation theory (MP2), employing an ANO-type basis set. In both cases a value of 12 kcal/ mol is obtained. The study firmly supports the hypothesis that the significance of the trigger reaction is to saturate a double bond in the vicinity of the enediyne group, which counteracts the formation of the biradical state of the drug. The MP2 computations became feasible by a novel implementation of an integral-direct, distributed-data, parallel MP2 algorithm.
引用
收藏
页码:203 / 210
页数:7
相关论文
共 50 条
  • [31] NEW APPROACH TO ANTI-CANCER DRUG DEVELOPMENT
    LANDES, RC
    BRITISH JOURNAL OF CANCER, 1975, 31 (02) : 254 - 254
  • [32] PET in anti-cancer drug development and therapy
    Kumar, Rakesh
    Lal, Neena
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (03) : 259 - 263
  • [33] CYTEMBENA - ANTI-CANCER DRUG WITH AN UNIQUE STRUCTURE
    VONHOFF, DD
    ROZENCWEIG, M
    MUGGIA, FM
    BIOMEDICINE, 1977, 26 (06): : 388 - 392
  • [34] New anti-cancer photosensitizer drug developed
    Kashyap, Meenakshi
    NATIONAL MEDICAL JOURNAL OF INDIA, 2007, 20 (03): : 161 - 161
  • [35] Atropisomerism transforming anti-cancer drug discovery
    Patel, Simran
    Sandha, Khushi
    Waingankar, Anushka
    Jain, Prachi
    Abhyankar, Arundhati
    CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 101 (01) : 138 - 157
  • [36] Computational approaches to anti-cancer drug design
    Taylor, SA
    Feldgus, S
    Shields, GC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U505 - U506
  • [37] Arsenic sulfide as a potential anti-cancer drug
    Ding, Wenping
    Zhang, Lian
    Kim, Sungkyoung
    Tian, Wei
    Tong, Yingying
    Liu, Jianwen
    Ma, Yong
    Chen, Siyu
    MOLECULAR MEDICINE REPORTS, 2015, 11 (02) : 968 - 974
  • [38] Extracellular vesicles and anti-cancer drug resistance
    Mc Namee, Niamh
    O'Driscoll, Lorraine
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (02): : 123 - 136
  • [39] Pharmacokinetic evaluation of a novel anti-cancer drug
    Donnarumma, F.
    Greilberger, J.
    Matzi, V.
    Lindenmann, J.
    Maier, A.
    Leis, H. -J.
    Wintersteiger, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 320 - 320
  • [40] Signalling Pathways in Anti-cancer Drug Resistance
    Chen, Chen
    Chen, Jiezhong
    Zhao, Kong-Nan
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3007 - 3008